Review article · 2018 · Open access
Clozapine as a first‐ or second‐line treatment in schizophrenia: a systematic review and meta‐analysis
Acta Psychiatrica Scandinavica, 138(4), 281–288 · Published 14 September 2018 · DOI 10.1111/acps.12954
In brief
“Clozapine as a first‐ or second‐line treatment in schizophrenia: a systematic review and meta‐analysis” is a 2018 review article by Cynthia Okhuijsen‐Pfeifer and 6 co-authors, published in Acta Psychiatrica Scandinavica. OpenAlex counts 92 citations as of 20 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at Acta Psychiatrica Scandinavica.
- Citations
- 92
- Most cited in
- 2020 (17)
- Field-weighted impact
- 1.05
- References
- 64
- Authors
- 7
Abstract
OBJECTIVE: No consensus exists on whether clozapine should be prescribed in early stages of psychosis. This systematic review and meta-analysis therefore focus on the use of clozapine as first-line or second-line treatment in non-treatment-resistant patients. METHODS: Articles were eligible if they investigated clozapine compared to another antipsychotic as a first- or second-line treatment in non-treatment-resistant schizophrenia spectrum disorders (SCZ) patients and provided data on treatment response. We performed random-effects meta-analyses. RESULTS: Fifteen articles were eligible for the systematic review (N = 314 subjects on clozapine and N = 800 on other antipsychotics). Our meta-analysis comparing clozapine to a miscellaneous group of antipsychotics revealed a significant benefit of clozapine (Hedges' g = 0.220, P = 0.026, 95% CI = 0.026-0.414), with no evidence of heterogeneity. In addition, a sensitivity analysis revealed a significant benefit of clozapine over risperidone (Hedges' g = 0.274, P = 0.030, 95% CI = 0.027-0.521). CONCLUSION: The few eligible trials on this topic suggest that clozapine may be more effective than other antipsychotics when used as first- or second-line treatment. Only large clinical trials may comprehensively probe disease stage-dependent superiority of clozapine and investigate overall tolerability.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Okhuijsen‐Pfeifer, C., Huijsman, E. A. H., Hasan, A., Sommer, I. E., Leucht, S., Kahn, R. S., & Luykx, J. J. (2018). Clozapine as a first‐ or second‐line treatment in schizophrenia: a systematic review and meta‐analysis. Acta Psychiatrica Scandinavica, 138(4), 281–288. https://doi.org/10.1111/acps.12954
MLA 9
Okhuijsen‐Pfeifer, Cynthia, et al. “Clozapine as a first‐ or second‐line treatment in schizophrenia: a systematic review and meta‐analysis.” Acta Psychiatrica Scandinavica, vol. 138, no. 4, 2018, pp. 281–288. https://doi.org/10.1111/acps.12954.
Chicago
Okhuijsen‐Pfeifer, Cynthia, Elianne A. H. Huijsman, Alkomiet Hasan, Iris E. Sommer, Stefan Leucht, René S. Kahn, and Jurjen Justin Luykx. 2018. “Clozapine as a first‐ or second‐line treatment in schizophrenia: a systematic review and meta‐analysis.” Acta Psychiatrica Scandinavica 138 (4): 281–288. https://doi.org/10.1111/acps.12954.
Harvard
Okhuijsen‐Pfeifer, C. et al. (2018) ‘Clozapine as a first‐ or second‐line treatment in schizophrenia: a systematic review and meta‐analysis’, Acta Psychiatrica Scandinavica, 138(4), pp. 281–288. doi:10.1111/acps.12954.
IEEE
C. Okhuijsen‐Pfeifer et al., “Clozapine as a first‐ or second‐line treatment in schizophrenia: a systematic review and meta‐analysis,” Acta Psychiatrica Scandinavica, vol. 138, no. 4, pp. 281–288, 2018, doi: 10.1111/acps.12954.
BibTeX
@article{okhuijsenpfeifer2018clozapine,
title = {{Clozapine as a first‐ or second‐line treatment in schizophrenia: a systematic review and meta‐analysis}},
author = {Okhuijsen‐Pfeifer, Cynthia and Huijsman, Elianne A. H. and Hasan, Alkomiet and Sommer, Iris E. and Leucht, Stefan and Kahn, René S. and Luykx, Jurjen Justin},
journal = {Acta Psychiatrica Scandinavica},
year = {2018},
volume = {138},
number = {4},
pages = {281--288},
doi = {10.1111/acps.12954},
url = {https://doi.org/10.1111/acps.12954}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2018 | 1 | |
| 2019 | 8 | |
| 2020 | 17 | |
| 2021 | 12 | |
| 2022 | 11 | |
| 2023 | 9 | |
| 2024 | 13 | |
| 2025 | 13 | |
| 2026 | 8 |
Its field-weighted citation impact is 1.05: it has been cited 1.05 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- clozapine
- schizophrenia
- first-line therapy
- second-line therapy
- antipsychotic drugs
- risperidone
- treatment-resistant schizophrenia
- early psychosis
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Okhuijsen‐Pfeifer, C., Huijsman, E. A. H., Hasan, A., Sommer, I. E., Leucht, S., Kahn, R. S., & Luykx, J. J. (2018). Clozapine as a first‐ or second‐line treatment in schizophrenia: a systematic review and meta‐analysis. Acta Psychiatrica Scandinavica, 138(4), 281–288. https://doi.org/10.1111/acps.12954
How many times has this paper been cited?
92 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Acta Psychiatrica Scandinavica: sign in and open the PDF from this page.
Who wrote this paper?
Cynthia Okhuijsen‐Pfeifer, Elianne A. H. Huijsman, Alkomiet Hasan, Iris E. Sommer, Stefan Leucht, René S. Kahn, Jurjen Justin Luykx.
What is the DOI of this paper?
10.1111/acps.12954, permanently at https://doi.org/10.1111/acps.12954. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.